Orchestra BioMed Holdings, Inc. Financial Instrument Subject to Mandatory Redemption, Par Value Per Share
Orchestra BioMed Holdings, Inc. (OBIO) had Financial Instrument Subject to Mandatory Redemption, Par Value Per Share of $10.02 per share as of 2022-06-30, per its 10-Q filed 2022-08-15.
Discontinued › Notes
us-gaap:FinancialInstrumentSubjectToMandatoryRedemptionParValuePerShare · last filed 2022-08-15
- 2022-06-30: Financial Instrument Subject to Mandatory Redemption, Par Value Per Share $10.02.
| Period end | Financial Instrument Subject to Mandatory Redemption, Par Value Per Share |
|---|---|
| 2022-06-30 | $10.02 10-Q · filed 2022-08-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SHOULDER INNOVATIONS, INC. (SI) | United States | $0.355B | |
| Orthofix Medical Inc. (OFIX) | $0.373B | ||
| Embecta Corp. (EMBC) | United States | $0.319B | 2.10 |
| CARLSMED, INC. (CARL) | United States | $0.405B | |
| TREACE MEDICAL CONCEPTS, INC. (TMCI) | United States | $0.297B | -4.32 |
| Mobia Medical, Inc. (MOBI) | United States | $0.293B | |
| TriSalus Life Sciences, Inc. (TLSI) | United States | $0.283B | -9.92 |
| Cytosorbents Corp (CTSO) | United States | $0.274B | -1.29 |
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |
| Anika Therapeutics, Inc. (ANIK) | United States | $0.272B | -51.71 |